Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.44 |
| ▸ | SCN4A | P35499 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13295257 | 0.82 | LMNA (0.45) | LMNAMTNR1AMTNR1BMAOAPTGS1 | |
| SCHEMBL21000898 | 0.74 | LMNA (0.58) | LMNAMTNR1AMTNR1BMAOAPTGS1 | |
| SCHEMBL17359116 | 0.73 | LMNA (0.49) | LMNAMTNR1AMTNR1BMAOAPTGS1 | |
| Benzamide SCHEMBL5823348 | 0.71 | PARP10 (0.53) | LMNAMTNR1AMTNR1BCYP2D6 | |
| Acetic Acid SCHEMBL28158342 | 0.70 | MTNR1A (0.60) | LMNAMTNR1AMTNR1BMAOAPTGS1 | |
| SCHEMBL10612565 | 0.70 | LMNA (0.58) | LMNAMTNR1AMTNR1BMAOAPTGS1 | |
| SCHEMBL6809829 | 0.70 | LMNA (0.58) | LMNAMTNR1AMTNR1BMAOAPTGS1 | |
| SCHEMBL16501753 | 0.70 | LMNA (0.49) | LMNAMTNR1AMTNR1BMAOAPTGS1 | |
| SCHEMBL4972800 | 0.70 | LMNA (0.45) | LMNAMTNR1AMTNR1BMAOAPTGS1 | |
| SCHEMBL15866588 | 0.70 | LMNA (0.62) | LMNAMTNR1AMTNR1BMAOAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179343-A1 | METHOD OF PRODUCING AN OPTICALLY ACTIVE CYANOHYDRIN DERIVATIVE | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179343-A1 | METHOD OF PRODUCING AN OPTICALLY ACTIVE CYANOHYDRIN DERIVATIVE | TDO2, AOX1, DAO | LMNA 3219/4885MTNR1A 2309/4885MTNR1B 3043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.